Wide Ranks

DNLI

Denali Therapeutics Inc.

25.16

Top Statistics
Market Cap 3 B Forward PE -8.62 Revenue Growth 0.00 %
Current Ratio 9.98 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -5.54 Enterprise / Revenue Price To Sales Trailing12 Months Infinity
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 836 M Total Cash Per Share 5.81 Total Debt 52 M
Total Debt To Equity 3.99 Current Ratio 9.98 Book Value Per Share 9.17
All Measures
Short Ratio 937.00 % Message Board Id finmb_301283598 Shares Short Prior Month 7 M
Return On Equity -0.3509 City South San Francisco Uuid 8e41e38b-ee3c-33f3-b430-d43094ba2e88
Previous Close 24.68 First Trade Date Epoch Utc 1 B Book Value 9.17
Beta 1.39 Total Debt 52 M Volume 559579
Price To Book 2.74 Fifty Two Week Low 14.56 Total Cash Per Share 5.81
Shares Short Previous Month Date 1 B Target Median Price 40.00 Audit Risk 2
Max Age 86400 Recommendation Mean 1.59 Sand P52 Week Change 0.3133
Target Mean Price 42.08 Net Income To Common -427492992 Short Percent Of Float 0.0577
Implied Shares Outstanding 143 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 1 M Average Volume10days 1 M Total Cash 836 M
Next Fiscal Year End 1 B Held Percent Insiders 0.0965 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 8
Regular Market Previous Close 24.68 Target Low Price 28.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 27.53 Open 25.27 Free Cashflow -212806496
State CA Dividend Yield 0.00 % Return On Assets -0.2381
Time Zone Short Name EST Board Risk 4 Trailing Eps -2.76
Day Low 24.78 Address1 161 Oyster Point Boulevard Shares Outstanding 143 M
Compensation Risk 8 Price Hint 2 Target High Price 90.00
Website https://www.denalitherapeutics.com 52 Week Change 0.3585 Average Volume 895109
Forward Eps -2.75 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 962.10 % Is_sp_500 False Regular Market Day High 25.42
Profit Margins 0.00 % Debt To Equity 3.99 Fifty Two Week High 33.33
Day High 25.42 Shares Short 7 M Regular Market Open 25.27
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.0493 Operating Cashflow -362636000 Currency USD
Time Zone Full Name America/New_York Market Cap 3 B Is_nasdaq_100 False
Zip 94080 Quote Type EQUITY Industry Biotechnology
Long Name Denali Therapeutics Inc. Overall Risk 6 Regular Market Day Low 24.78
Held Percent Institutions 0.9059 Current Price 25.16 Enterprise To Ebitda -5.54
Financial Currency USD Current Ratio 9.98 Industry Disp Biotechnology
Number Of Analyst Opinions 13 Country United States Float Shares 130 M
Two Hundred Day Average 22.72 Governance Epoch Date 1 B Enterprise Value 2 B
Price To Sales Trailing12 Months Infinity Forward PE -8.62 Regular Market Volume 559579
Ebitda -511854016 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States.

The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases.

It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs.

The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.

b.

H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015.

Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.